<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Nerve stimulation</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>9/11 first responders with PTSD may get help from vagus nerve stimulator</title>
      <description>
        <![CDATA[The NIH and CDC granted researchers at the Feinstein Institutes for Medical Research at Northwell Health $700,000 to investigate an in-the-ear stimulator as a treatment for post-traumatic stress disorder (PTSD) in first responders to the attack on the World Trade Center 20 years ago. The researchers will enroll 30 World Trade Center first responders with chronic PTSD in a sham-controlled trial to test the effectiveness of a device that uses transcutaneous auricular stimulation of the vagus nerve, which has shown promise in preclinical studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511308</guid>
      <pubDate>Fri, 10 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511308-9-11-first-responders-with-ptsd-may-get-help-from-vagus-nerve-stimulator</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/09-10-Nesos-VNS.webp?t=1631309614" type="image/png" medium="image" fileSize="192541">
        <media:title type="plain">Earbud device for VNS</media:title>
        <media:description type="plain">Feinstein Institutes’ researchers will be using a vagus nerve stimulator developed by Nēsos.</media:description>
      </media:content>
    </item>
    <item>
      <title>Liver-focused ultrasound stimulation could reduce obesity and inflammation</title>
      <description>
        <![CDATA[Stimulating the liver with focused ultrasound decreased obesity, chronic inflammation and metabolic dysfunction in preclinical studies, reported GE Research and the Feinstein Institutes for Medical Research, the research arm of Northwell Health. In a study published in <em>Scientific Reports</em>, researchers demonstrated that nerve modulation with ultrasound in mice helped regulate neurons involved in food intake, glucose regulation and metabolism without negative side effects.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504561</guid>
      <pubDate>Tue, 09 Mar 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504561-liver-focused-ultrasound-stimulation-could-reduce-obesity-and-inflammation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-09-Liver-Ultrasound.webp?t=1615329591" type="image/png" medium="image" fileSize="1583336">
        <media:title type="plain">Ultrasound set-up used in obesity and inflammation study</media:title>
        <media:description type="plain">Researchers demonstrated that ultrasound technology could be used as a noninvasive approach to treating obesity. Credit: The Feinstein Institutes for Medical Research</media:description>
      </media:content>
    </item>
    <item>
      <title>Feinstein researchers develop method to activate specific fibers in vagus nerve</title>
      <description>
        <![CDATA[Researchers at the Feinstein Institutes for Medical Research, the research arm of New York-based Northwell Health, have developed a noninvasive method for targeting stimulation of the vagus nerve. Vagus nerve stimulation (VNS) offers promise for treatment of a wide range of conditions, given the nerve&#39;s extensive involvement in regulating many organs, but has been constrained by adverse effects caused by off-target activation of fibers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/498524</guid>
      <pubDate>Fri, 02 Oct 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/498524-feinstein-researchers-develop-method-to-activate-specific-fibers-in-vagus-nerve</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/10-2-Feinstein-vagus-nerve.webp?t=1601677021" type="image/png" medium="image" fileSize="375658">
        <media:title type="plain">Illustration of vagus nerve, organs</media:title>
        <media:description type="plain">The vagus nerve regulates communication between the brain and major organs. Source: Biology dictionary.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sleep disorder company Nyxoah clears $100M in IPO</title>
      <description>
        <![CDATA[LONDON &ndash; Sleep disorder specialist Nyxoah SA hit the top end of its price range of &euro;17 per share, raising &euro;84.75 million (US$100) million in its initial public offering. Assuming full exercise of the over-allotment option, the company will have a market capitalization of &euro;375.26 million. The shares began trading on Euronext Brussels (EBR:NYXH) on Sept. 18, and had a good first day, closing up 14.7%, at &euro;19.50.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497976</guid>
      <pubDate>Fri, 18 Sep 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497976-sleep-disorder-company-nyxoah-clears-100m-in-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-puzzle-pieces.webp?t=1594411157" type="image/png" medium="image" fileSize="214047">
        <media:title type="plain">IPO puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Bluewind Medical kicks off overactive bladder study with Renova Istim</title>
      <description>
        <![CDATA[Israeli startup Bluewind Medical Ltd. has begun enrolling patients at U.S. sites in a pivotal trial of its Renova Istim implantable tibial neuromodulation system for the treatment of overactive bladder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/496672</guid>
      <pubDate>Tue, 11 Aug 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496672-bluewind-medical-kicks-off-overactive-bladder-study-with-renova-istim</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/8-11-bluewind-medical-renova.webp?t=1597184614" type="image/png" medium="image" fileSize="301273">
        <media:title type="plain">Diagram illustrating Renova system components</media:title>
        <media:description type="plain">Renova Istim. Credit: Bluewind Medical Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA greenlights Interstim Micro and Surescan MRI leads for bladder and bowel control</title>
      <description>
        <![CDATA[Medtronic plc has won U.S. FDA approval of its Interstim Micro rechargeable sacral nerve stimulator and Interstim Surescan MRI leads for the treatment of urinary and bowel dysfunctions. The new products make Medtronic the only company to offer a choice between rechargeable and recharge-free sacral neuromodulation (SNM) systems, allowing patients to align their treatment with personal lifestyle preferences.]]>
      </description>
      <guid>http://www.bioworld.com/articles/496432</guid>
      <pubDate>Mon, 03 Aug 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496432-fda-greenlights-interstim-micro-and-surescan-mri-leads-for-bladder-and-bowel-control</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/8-3-medtronic-interstim.webp?t=1596492550" type="image/png" medium="image" fileSize="404783">
        <media:title type="plain">Product images</media:title>
        <media:description type="plain">Interstim Micro, Interstim II, and Interstim Surescan MRI leads. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Setpoint to start U.S. pivotal trial for RA implant around year end</title>
      <description>
        <![CDATA[A bioelectronic platform that stimulates the vagus nerve to reduce inflammatory activity and restore balance in the immune system is the ultimate aim of Setpoint Medical Inc. The Valencia, Calif.-based startup is preparing to start a U.S. pivotal trial for its most advanced program in rheumatoid arthritis (RA) later this year or early next.]]>
      </description>
      <guid>http://www.bioworld.com/articles/496400</guid>
      <pubDate>Fri, 31 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496400-setpoint-to-start-us-pivotal-trial-for-ra-implant-around-year-end</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/7-31-Setpoint-Bioelectrical-Engineering-system.webp?t=1596231226" type="image/png" medium="image" fileSize="1155979">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">The bioelectronic platform consists of an implantable Microregulator, a wireless charging collar or band, and an Ipad-based prescription application. Credit: Setpoint Medical Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA grants emergency use of Gammacore for asthma in COVID-19 patients</title>
      <description>
        <![CDATA[Electrocore Inc. has snagged an emergency use authorization (EUA) from the U.S. FDA for use of its Gammacore Sapphire CV noninvasive vagus nerve stimulation (nVNS) to acutely treat asthma exacerbations in known or suspected COVID-19 patients. The hand-held therapy can be used at home and in a health care setting.]]>
      </description>
      <guid>http://www.bioworld.com/articles/443569</guid>
      <pubDate>Mon, 13 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/443569-fda-grants-emergency-use-of-gammacore-for-asthma-in-covid-19-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-24-electrocore-gammacore-sapphire.webp?t=1594677765" type="image/png" medium="image" fileSize="1325914">
        <media:title type="plain">Man using Gammacore device on neck</media:title>
        <media:description type="plain">Gammacore Sapphire device. Credit: Electrocore Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives green light to Mainstay Medical’s Reactiv8 device</title>
      <description>
        <![CDATA[Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved Reactiv8 as an aid in managing intractable chronic low back pain associated with multifidus muscle dysfunction in adults who have failed therapy and are not candidates for spine surgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435966</guid>
      <pubDate>Mon, 22 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435966-fda-gives-green-light-to-mainstay-medicals-reactiv8-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-22-Mainstay-Medical-Reactiv8.webp?t=1592855966" type="image/png" medium="image" fileSize="1109349">
        <media:title type="plain">Reactiv8 device on spine model</media:title>
        <media:description type="plain">Reactiv8 implantable neurostimulation device.
Credit: Mainstay Medical Holdings plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Gtx Medical receives breakthrough device designation for implanted spinal stimulation system</title>
      <description>
        <![CDATA[The U.S. FDA granted Gtx Medical BV a breakthrough device designation for its implantable Go-2 Targeted Epidural Spinal Stimulation (TESS) system. The device enabled patients who had sustained traumatic spinal cord injuries to regain voluntary control over previously paralyzed muscles and walk again four or more years after paralysis, according to a study previously published in <em>Nature</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435708</guid>
      <pubDate>Wed, 10 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435708-gtx-medical-receives-breakthrough-device-designation-for-implanted-spinal-stimulation-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-10-Gtx-Go-2.webp?t=1591827545" type="image/png" medium="image" fileSize="299383">
        <media:title type="plain">Components of the Go-2 system</media:title>
        <media:description type="plain">Go-2 Targeted Epidural Spinal Stimulation system.
Credit: Gtx Medical BV</media:description>
      </media:content>
    </item>
    <item>
      <title>Feinstein Institutes research demonstrates next step in bioelectronic medicine</title>
      <description>
        <![CDATA[Researchers at New York-based Feinstein Institutes for Medical Research, the research arm of Northwell Health, showed that anodal block can be used for directional vagus nerve stimulation (VNS) in a new paper in <em>Scientific Reports</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435679</guid>
      <pubDate>Tue, 09 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435679-feinstein-institutes-research-demonstrates-next-step-in-bioelectronic-medicine</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-9-bioelectronic-medicine.webp?t=1591739889" type="image/png" medium="image" fileSize="1596662">
        <media:title type="plain">Bioelectronic medicine infographic</media:title>
        <media:description type="plain">The bioelectronic medicine model </media:description>
      </media:content>
    </item>
    <item>
      <title>Axonics looks to expand reach with its r-SNM system</title>
      <description>
        <![CDATA[Irvine, Calif.-based Axonics Modulation Technologies Inc., which is marketing implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, reported the submission of a premarket approval (PMA) supplement. Specifically, it is looking to gain full-body magnetic resonance imaging-conditional labeling for 3.0 Tesla (T) MRI scans.]]>
      </description>
      <guid>http://www.bioworld.com/articles/434220</guid>
      <pubDate>Mon, 06 Apr 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/434220-axonics-looks-to-expand-reach-with-its-r-snm-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Axonics-r-snm-11-18.webp?t=1574058160" type="image/jpeg" medium="image" fileSize="289933">
        <media:title type="plain">Axonics-r-snm-11-18.jpg</media:title>
        <media:description type="plain">r-SNM system. Credit: Axonics Modulation Technologies Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Livanova teams up with Verily on depression trial</title>
      <description>
        <![CDATA[London-based Livanova plc has entered a collaboration with Verily Inc., an Alphabet company, to enrich data from its RECOVER trial using tools and analytics developed by Verily. The study, which kicked off last September, is assessing the effectiveness of vagus nerve stimulation (VNS) therapy for patients with difficult-to-treat depression (DTD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/433374</guid>
      <pubDate>Thu, 27 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433374-livanova-teams-up-with-verily-on-depression-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/2-27-Livanova-Symmetry.webp?t=1582843832" type="image/png" medium="image" fileSize="678579">
        <media:title type="plain">2-27-Livanova-Symmetry.png</media:title>
        <media:description type="plain">Symmetry vagus nerve stimulation system. Credit: Livanova plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Nevro shines following quarterly results, positive news on NSRBP study</title>
      <description>
        <![CDATA[Nevro Corp.&rsquo;s stock was up following encouraging results detailed during its fourth-quarter earnings call. Management predicted a positive 2020, highlighting the potential of the U.S. spinal cord stimulation (SCS) market. Keith Grossman, chair, CEO and president of the company, noted that the SCS market slowed last year as a result of stocking issues &ndash; a challenge that affected both it and its competitors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433333</guid>
      <pubDate>Wed, 26 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433333-nevro-shines-following-quarterly-results-positive-news-on-nsrbp-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/2-26-Nevro-Omnia.webp?t=1582755177" type="image/png" medium="image" fileSize="453214">
        <media:title type="plain">2-26-Nevro-Omnia.png</media:title>
        <media:description type="plain">Omnia system. Credit: Nevro Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Micro-leads raises $10M to develop and test precision spinal cord stimulation</title>
      <description>
        <![CDATA[Spinal cord stimulation to treat pain has long been associated with mixed efficacy and substantial side effects such as paresthesia, which is an unpleasant tingly or prickly sensation. Redwood City, Calif.-based Nevro Corp. famously has built a multi-billion-dollar business on next-gen, pain neurostimulation technology that improves efficacy and reduces side effects. Sommerville, Mass.-based Micro-leads Medical Inc. hopes that it could be next in successfully further refining spinal cord stimulation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/431583</guid>
      <pubDate>Thu, 05 Dec 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431583-micro-leads-raises-10m-to-develop-and-test-precision-spinal-cord-stimulation</link>
    </item>
    <item>
      <title>Medtronic files for FDA approval of Interstim Micro, Surescan MRI leads</title>
      <description>
        <![CDATA[Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI leads. Interstim Micro is intended to help patients with overactive bladder (OAB), urinary urge incontinence, unobstructed urinary retention and  fecal incontinence (FI).]]>
      </description>
      <guid>http://www.bioworld.com/articles/430289</guid>
      <pubDate>Tue, 08 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430289-medtronic-files-for-fda-approval-of-interstim-micro-surescan-mri-leads</link>
    </item>
    <item>
      <title>Axonics looks to take on Medtronic after getting FDA nod for r-SNM system</title>
      <description>
        <![CDATA[Irvine, Calif.-based Axonics Modulation Technologies Inc., which has developed an implantable rechargeable sacral neuromodulation (r-SNM) device for the treatment of urinary and bowel dysfunction, has won the FDA's nod for its system to help patients with fecal incontinence.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430241</guid>
      <pubDate>Tue, 10 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430241-axonics-looks-to-take-on-medtronic-after-getting-fda-nod-for-r-snm-system</link>
    </item>
  </channel>
</rss>
